{{Refimprove|date=December 2009}}
{{Drugbox
| verifiedrevid = 460022605
| IUPAC_name = (6''R'',7''R'')-3-[(acetoxy)methyl]-8-oxo-7-[(2-thienylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
| image = Cefalotin.svg
| width = 300
<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|international|cefalotin}}
| MedlinePlus = a682860
| pregnancy_US = B
| pregnancy_AU = A
| legal_AU = S4
| legal_UK = POM
| routes_of_administration = [[Intravenous therapy|Intravenous]]
<!--Pharmacokinetic data-->
| bioavailability = n/a
| protein_bound = 65 to 80%
| metabolism = [[Liver|Hepatic]]
| elimination_half-life = 30 minutes to 1 hour
| excretion = [[Kidney|Renal]]
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 153-61-7
| ATC_prefix = J01
| ATC_suffix = DB03
| PubChem = 6024
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00456
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 5802
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = R72LW146E6
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07635
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 124991
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 617
<!--Chemical data-->
| C=16 | H=16 | N=2 | O=6 | S=2
| molecular_weight = 396.44 g/mol
| smiles = O=C2N1/C(=C(\CS[C@@H]1[C@@H]2NC(=O)Cc3sccc3)COC(=O)C)C(=O)O
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C16H16N2O6S2/c1-8(19)24-6-9-7-26-15-12(14(21)18(15)13(9)16(22)23)17-11(20)5-10-3-2-4-25-10/h2-4,12,15H,5-7H2,1H3,(H,17,20)(H,22,23)/t12-,15-/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = XIURVHNZVLADCM-IUODEOHRSA-N
}}

'''Cefalotin''' ([[International Nonproprietary Name|INN]]) {{IPAc-en|ˌ|s|ɛ|f|ə|ˈ|l|oʊ|t|ᵻ|n}} or '''cephalothin''' ([[United States Adopted Name|USAN]]) {{IPAc-en|ˌ|s|ɛ|f|ə|ˈ|l|oʊ|θ|ᵻ|n}} is a first-generation [[cephalosporin]] [[antibiotic]].<ref>{{Cite journal
 | pmid = 18159398
| pmc = 2094874
| year = 2002
| author1 = Hameed
| first1 = T. K.
| title = Review of the use of cephalosporins in children with anaphylactic reactions from penicillins
| journal = The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses
| volume = 13
| issue = 4
| pages = 253–8
| last2 = Robinson
| first2 = J. L.
}}</ref> It was the first cephalosporin marketed (1964) and continues to be widely used.<ref name="Greenwood2008">{{cite book|author=David Greenwood|title=Antimicrobial Drugs: Chronicle of a Twentieth Century Medical Triumph|url=https://books.google.com/books?id=i4_FZHmzjzwC&pg=PA128|date=21 February 2008|publisher=OUP Oxford|isbn=978-0-19-953484-5|pages=128–}}</ref> It is an [[intravenous]]ly administered agent with a similar antimicrobial spectrum to [[cefazolin]] and the oral agent [[cefalexin]]. '''Cefalotin sodium''' is marketed as '''Keflin''' ([[Eli Lilly and Company|Lilly]]) and under other trade names.<ref>{{drugs.com|international|cefalotin}}: Cefalotin</ref>

==References==
{{reflist}}

{{CephalosporinAntiBiotics}}

[[Category:Cephalosporin antibiotics]]
[[Category:Eli Lilly and Company]]
[[Category:Thiazoles]]
[[Category:Acetate esters]]


{{Antibiotic-stub}}